-
1دورية أكاديميةRosuvastatin therapy does not affect serum MMP-13 or TIMP-1 levels in hypercholesterolemic patients.
المؤلفون: Cevik C; Department of Adult Cardiology, Texas Heart Institute at St. Luke's Episcopal Hospital, Houston, Texas 77030, USA., Nugent K, Meyerrose G, Otahbachi M, Izgi C, Lyte M, Fish RD
المصدر: Texas Heart Institute journal [Tex Heart Inst J] 2011; Vol. 38 (3), pp. 229-33.
نوع المنشور: Journal Article
بيانات الدورية: Publisher: published in the Cardiovascular Surgical Research Laboratories, Texas Heart Institute Country of Publication: United States NLM ID: 8214622 Publication Model: Print Cited Medium: Internet ISSN: 1526-6702 (Electronic) Linking ISSN: 07302347 NLM ISO Abbreviation: Tex Heart Inst J Subsets: MEDLINE
مواضيع طبية MeSH: Fluorobenzenes/*therapeutic use , Hydroxymethylglutaryl-CoA Reductase Inhibitors/*therapeutic use , Hypercholesterolemia/*drug therapy , Matrix Metalloproteinase 13/*blood , Pyrimidines/*therapeutic use , Sulfonamides/*therapeutic use , Tissue Inhibitor of Metalloproteinase-1/*blood, Adult ; Aged ; Cholesterol, LDL/blood ; Female ; Humans ; Hypercholesterolemia/enzymology ; Male ; Middle Aged ; Pilot Projects ; Prospective Studies ; Rosuvastatin Calcium ; Texas ; Time Factors ; Treatment Outcome